Ebola virus pathogenesis: implications for vaccines and therapies.
作者信息
Sullivan Nancy, Yang Zhi-Yong, Nabel Gary J
机构信息
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 40, Room 4502, MSC 3005, 40 Convent Drive, Bethesda, MD 20892-3005, USA.
出版信息
J Virol. 2003 Sep;77(18):9733-7. doi: 10.1128/jvi.77.18.9733-9737.2003.
Abstract
摘要
相似文献
1
Ebola virus pathogenesis: implications for vaccines and therapies.
J Virol. 2003 Sep;77(18):9733-7. doi: 10.1128/jvi.77.18.9733-9737.2003.
2
The pathogenesis of Ebola hemorrhagic fever.
Trends Microbiol. 2001 Oct;9(10):506-11. doi: 10.1016/s0966-842x(01)02201-6.
3
Ebola Therapeutic Study and Future Directions.
Infect Disord Drug Targets. 2019;19(1):17-29. doi: 10.2174/1871526518666180813160348.
4
Ebola virus: the search for vaccines and treatments.
Cell Mol Life Sci. 2001 Nov;58(12-13):1826-41. doi: 10.1007/PL00000821.
5
Ebola virus: from discovery to vaccine.
Nat Rev Immunol. 2003 Aug;3(8):677-85. doi: 10.1038/nri1154.
6
[Hope for a vaccine against ebola virus].
Pharm Unserer Zeit. 2001;30(3):185-6.
7
A single shot against Ebola and Marburg virus.
Nat Med. 2005 Jul;11(7):720-1. doi: 10.1038/nm0705-720.
8
Towards a vaccine against Ebola virus.
Expert Rev Vaccines. 2003 Dec;2(6):777-89. doi: 10.1586/14760584.2.6.777.
9
Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
J Virol. 2018 May 14;92(11). doi: 10.1128/JVI.00363-18. Print 2018 Jun 1.
10
Fast vaccine offers hope in battle with Ebola.
Nature. 2003 Aug 7;424(6949):602. doi: 10.1038/424602a.
引用本文的文献
1
Retrospective Comparison of Nigeria's Emergency Response Between the 2014 Ebola Outbreak and 2020 COVID-19 Pandemic.
Cureus. 2023 Aug 29;15(8):e44300. doi: 10.7759/cureus.44300. eCollection 2023 Aug.
2
MATHEMATICAL MODELLING APPROACH OF THE STUDY OF EBOLA VIRUS DISEASE TRANSMISSION DYNAMICS IN A DEVELOPING COUNTRY.
Afr J Infect Dis. 2022 Dec 22;17(1):10-26. doi: 10.21010/Ajidv17i1.2. eCollection 2023.
3
Comparative overview of emerging RNA viruses: Epidemiology, pathogenesis, diagnosis and current treatment.
Ann Med Surg (Lond). 2022 Jul;79:103985. doi: 10.1016/j.amsu.2022.103985. Epub 2022 Jun 11.
4
Antiviral Polymers: A Review.
Polymers (Basel). 2022 Apr 19;14(9):1634. doi: 10.3390/polym14091634.
5
Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?
Front Immunol. 2021 May 11;12:673699. doi: 10.3389/fimmu.2021.673699. eCollection 2021.
6
Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection.
Front Immunol. 2021 Feb 19;11:599568. doi: 10.3389/fimmu.2020.599568. eCollection 2020.
7
Development of a Well-Characterized Rhesus Macaque Model of Ebola Virus Disease for Support of Product Development.
Microorganisms. 2021 Feb 26;9(3):489. doi: 10.3390/microorganisms9030489.
8
Investigating the Interaction between Negative Strand RNA Viruses and Their Hosts for Enhanced Vaccine Development and Production.
Vaccines (Basel). 2021 Jan 17;9(1):59. doi: 10.3390/vaccines9010059.
9
Clinical and epidemiological performance of WHO Ebola case definitions: a systematic review and meta-analysis.
Lancet Infect Dis. 2020 Nov;20(11):1324-1338. doi: 10.1016/S1473-3099(20)30193-6. Epub 2020 Jun 25.
10
Synthesis and Structure-Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3- b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity.
J Med Chem. 2019 Jun 27;62(12):5810-5831. doi: 10.1021/acs.jmedchem.9b00136. Epub 2019 Jun 12.
本文引用的文献
1
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.
Nature. 2003 Aug 7;424(6949):681-4. doi: 10.1038/nature01876.
2
DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells.
Virology. 2003 Jan 5;305(1):115-23. doi: 10.1006/viro.2002.1730.
3
Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor.
Virology. 2002 Nov 10;303(1):9-14. doi: 10.1006/viro.2002.1715.
4
C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans.
J Virol. 2002 Jul;76(13):6841-4. doi: 10.1128/jvi.76.13.6841-6844.2002.
5
Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.
J Virol. 2002 Jun;76(12):6408-12. doi: 10.1128/jvi.76.12.6408-6412.2002.
6
Evaluation in nonhuman primates of vaccines against Ebola virus.
Emerg Infect Dis. 2002 May;8(5):503-7. doi: 10.3201/eid0805.010284.
7
Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence.
J Virol. 2002 Mar;76(5):2518-28. doi: 10.1128/jvi.76.5.2518-2528.2002.
8
Infection and activation of monocytes by Marburg and Ebola viruses.
J Virol. 2001 Nov;75(22):11025-33. doi: 10.1128/JVI.75.22.11025-11033.2001.
9
Folate receptor-alpha is a cofactor for cellular entry by Marburg and Ebola viruses.
Cell. 2001 Jul 13;106(1):117-26. doi: 10.1016/s0092-8674(01)00418-4.
10
Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.
J Virol. 2001 May;75(10):4649-54. doi: 10.1128/JVI.75.10.4649-4654.2001.
Zotero 插件